Klinische Erfahrungen mit der Immunzytologie mit dem monoklonalen Antikörper 486 P (Medaquic®) beim Urothelkarzinom der Blase

jedoch bei Anwendung beider Verfah ren möglich. Clinical Experience with Immunocytology using Monoclo nal Antibody 486 P (Medaquic® in Detection of Bladder Cancer: Recent studies suggest that immunocytology may offer an improvement in the detection-rate of bladder Cancer over that of conventional cytology. We therefore investigated 96 cases of histologically proven bladder Cancer (TCC) with the monoclonal antibody (mAb) 486 P. In G1 -TCC (n = 16) 56.3 % were detected by cytology and 62.5% by immunocytology. In G2-TCC (n = 48) 75,0% were detected by cytology and 77,1% bei immunocyto logy. Cytology showed malignant cells in 90.6% of G3-TCC (n = 32), 75.0% of these cases were positive by means of immu nocytology. There was no significant difference between cyto logy and immunocytology, however, the combination of both methods (either positive result in cytology or in immunocyto logy) was superior to conventional cytology. 87.5% of G1-TCC and 91.7% of G2-TCC were detected by cytology or immunocyto logy vs. 56.3% and 75.0%, respectively, by conventional cyto logy. In our opinion conventional cytology cannot be replaced by immunocytology with mAb 486 P, but the combination of both methods is capable to improve the detection-rate of G1 - and G2-TCC.